This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026
We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available. 3
What this version reported
At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.↗
Organizations named in cited records:
- U.S. Food and Drug Administration↗
Sources for this version
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 3FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗
U.S. Food and Drug Administration · Official source · Source checked September 15, 2026